ELTX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Elicio Therapeutics Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.80 USD
-6.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -68.4% below the Trend Line and sits at 1.0% of its 52-week range. The latest completed week returned -6.7%, after a -13.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 18 out of 100
Latest Close 2.80 USD 31 Jul 2026
1W Return -6.7% latest completed week
4W Return -13.0% short-term follow-through
12W Return -71.7% quarterly tape
Trend Breadth 51.9% 27 of 52 weeks active
Volume Ratio 0.2x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.7% Latest completed week; four-week move -13.0%. Indicator stack 29/20 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 42/100 conviction; expected move 30.0%. News sentiment 47/100 54 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -68.4% below the Trend Line and sits at 1.0% of its 52-week range. The latest completed week returned -6.7%, after a -13.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2612-week average 0.44

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.26Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -13.0% over four weeks, -71.7% over 12 weeks, and -71.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-6.7%
4W-13.0%
12W-71.7%
26W-63.2%
52W-71.9%
Active trend streak0 weeks
Active weeks in one year27
Trend breadth51.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.28Latest activity-pressure read.
Pressure change-92.9%Four-week change in activity pressure.
Leadership-72.46Latest relative-leadership reading.
RS change-1.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 58% Model confidence 55%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength81/100Blend of value, momentum, and quality. Underlying universe rank 20; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality64/100Profitability and accounting quality. Underlying universe rank 37; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-49.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-29.7%
Net share repurchases relative to market value.
Shareholder yield
-29.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ELTX shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.16, expected move of 30.0%, and Sharemaestro trend signal inactive.

Conviction42/100
Expected move30.0%
Put/call volume0.16
Pressure77
Speculation0
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment47/100

Weighted news tone is neutral across 54 relevant articles.

8 positive · 34 neutral · 12 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move30.0%Nearest-chain priced movement where available.
52-week drawdown-82.5%Distance below the 52-week high.
13-week volatility22.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+48.5%Week of 27 Feb.
Worst week-74.1%Week of 19 Jun.
Latest week-6.7%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains4
Flat weeks0
Modest losses2
Sharp losses11
Recent vol22.5%13-week weekly-return volatility.
Base vol15.4%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew8.9% / -9.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 6/12, activity pressure 3/12, relative leadership 2/12.

Activity pressure 0.26; 2 reversal markers Factors68/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 44 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options42/100

ELTX shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.16, expected move of 30.0%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 30.0% Sentiment47/100

Weighted news tone is neutral across 54 relevant articles.

Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.80 USD-6.7%8.87 USD7.42 USD-1.28-72.461.5MOff
24 Jul 20263.00 USD-3.5%9.04 USD7.46 USD-1.28-70.861.4MOff
17 Jul 20263.11 USD-10.6%9.21 USD7.51 USD-1.29-70.773.3MOff
10 Jul 20263.48 USD8.1%9.37 USD7.55 USD-1.18-69.128.4MOff
3 Jul 20263.22 USD-19.5%9.53 USD7.59 USD-0.66-71.267.5MOff
26 Jun 20264.00 USD3.9%9.69 USD7.64 USD-0.24-64.428.5MOff
19 Jun 20263.85 USD-74.1%9.87 USD7.68 USD0.01-67.6468.8MOn
12 Jun 202614.85 USD12.0%10.02 USD7.72 USD0.1326.62780.1KOn
5 Jun 202613.26 USD15.9%9.82 USD7.70 USD-0.0316.51773.2KOn
29 May 202611.44 USD15.0%9.68 USD7.72 USD-0.17-3.55511.7KOn
22 May 20269.95 USD-6.4%9.60 USD7.76 USD-0.01-13.53643.2KOn
15 May 202610.63 USD7.3%9.60 USD7.76 USD0.19-6.19951.1KOn
8 May 20269.91 USD-7.8%9.55 USD7.74 USD0.45-12.33539.5KOn
1 May 202610.75 USD-8.0%9.58 USD7.73 USD0.590.66707.3KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.